# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Despite modest adjustments to the quarterly gating in 2024, the Company's outlook for the year remains essentially unchang...
Charles River (NYSE:CRL) reported quarterly earnings of $2.27 per share which beat the analyst consensus estimate of $2.07 by 9...
Supporting scale-up for early-phase AAV- and LVV-based gene and gene-modified cell therapy researchers and developersCharles Ri...
This agreement comes ahead of entering into an anticipated master services agreement for the development and manufacture of Fib...
GMP grade plasmid DNA to serve as a direct therapeutic targeting various indicationsCharles River Laboratories International, I...